CSAAI 2025 Educational Meeting: A Midsummer Night’s Wheeze

Huntington Beach, CA US
June 28, 2025 to June 29, 2025

It is an exciting time in the field of allergy and immunology.  This CME/CE program is designed to allow attendees to continue exploring the field.  Covered topics include Food Allergy, Hereditary Angioedema, Asthma, Immune Deficiency and more!

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the California Society of Allergy, Asthma & Immunology (CSAAI).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 6.5 contact hours.

No commercial support was received for this activity.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this activity learners should be able to…
1. Formulate a diagnostic approach for a patient suspected of having HAE
2. Assess the benefits and limitations of the available treatments for HAE.
3. Organize a comprehensive treatment plan for patients with HAE.
4. Prepare to discuss advances, expectations and limitations with your food allergic patients
5. Identify appropriate patients for food challenges and recent advances in OIT, SLIT
6. Evaluate and select evolving therapeutic strategies for asthma patients
7. Review mechanisms, current asthma biologics and their effects
8. Evaluate current clinical data indicating/suggesting possible remittive effects of biologics in asthma
9. Describe the cardinal manifestations of immune deficiencies and how to distinguish these immune defects.
10. Review treatments used for immunodeficiency
11. Review the pathophysiologic mechanisms underlying innate immunity defects

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Attendance
  • 6.50 CBRN
Course opens: 
06/28/2025
Course expires: 
12/31/2025
Event starts: 
06/28/2025 - 12:00pm CDT
Event ends: 
06/29/2025 - 11:30am CDT
Add to calendar: 
Rating: 
0

CSAAI 2025 Educational Meeting, A Midsummer Night’s Wheeze
June 28-29, 2025
Huntington Beach CA

All Education Sessions to be held in Huntington South
Exhibits and Coffee Breaks to be held in Huntington North

SATURDAY, JUNE 28

7:00am-2:15pm  Registration

7:15am-8:45am  Exhibits & Continental Breakfast

8:45am-9:00am  Welcome & Overview, Sonal Patel, MD  

9:00am-9:40am Hereditary Angioedema / Q&A
Jonathan A. Bernstein, MD

9:40am-10:20am NK Cell Deficiency / Q&A
Jordan S. Orange, MD, PhD

10:20am-11:00am    Town Hall: Advocacy Update / Q&A - Brought to you by the American College of Allergy, Asthma & Immunology             
Warner Carr, MD

11:00am-12:15pm    Lunch Break and Exhibits

12:15pm-12:55pm    Practice Management / Q&A - Brought to you by the American College of Allergy, Asthma & Immunology
Warner Carr, MD    

12:55pm-1:35pm    Allergic Airway / Q&A
Michael Manning, MD

1:35pm-2:15pm  Food Allergy / Q&A
Maeve O’Connor, MD

2:15pm  Adjourn

SUNDAY, JUNE 29

7:00am-7:50am  Continental Breakfast & Exhibits

7:50am-8:00am  Overview, Raffi Tachdjian, MD, MPH, Program Director

8:00am-8:40am  Is it Asthma or Something Else? Lung Diseases Masquerading as Asthma / Q&A
Jonathan A Bernstein, MD

8:40am-9:20am  The Developing Practice Parameter in Immune Deficiency / Q&A
Jordan S. Orange, MD, PhD

9:20am-9:50am  Coffee Break & Exhibits

9:50am-10:30am  Atopic Dermatitis / Q&A         
Maeve O‘Connor

10:30am-11:10pm  Chronic Urticaria Update / Q&A               
Michael Manning, MD
        
11:10am-11:20pm  Closing Remarks, Sonal Patel, MD, President CSAAI

11:20am  Adjourn

Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA 92648
United States

All relevant financial relationships with ineligible companies have been mitigated.

Jonathan A. Bernstein, MD – Speaker
Advisor: Amgen, AstraZeneca, BioCryst, Blueprint Medicines, Merck, Novartis, Pharming, Regeneron, Roche, Sanofi, Takeda, Ionis, Celldex, KalVista, Biomarin, Jasper & Escient Pharmaceuticals, CSL Behring, DBV Technologies, Dermavant, Ely Lilly, Genentech, GSK, Johnson & Johnson
Consultant: Amgen, AstraZeneca, BioCryst, Blueprint Medicine, Merck, Novartis, Pharming, Regeneron, Roche, Sanofi, Takeda, Ionis, Celldex, KalVista, Biomarin, Jasper & Escient Pharmaceuticals, CSL Behring, DBV Technologies, Dermavant, Ely Lilly, Genentech, GSK, Johnson & Johnson
Researcher: Amgen, AstraZeneca, BioCryst, Blueprint Medicine, Merck, Novartis, Pharming, Regeneron, Roche, Sanofi, Takeda, Teva, Ionis, Celldex, KalVista, Biomarin, Jasper & Escient Pharmaceuticals, CSL Behring, DBV Technologies, Dermavant, Genentech, GSK

Warner Carr, MD – Speaker
Advisor: AstraZeneca, Blueprint Medicine, Genentech, Novartis, Regeneron
Consultant: AstraZeneca, Blueprint Medicine, Genentech, Novartis, Regeneron, Sanofi
Independent Contractor: Sanofi
Speaker: Sanofi

Michael E. Manning, MD – Speaker
Advisor: Astria,  BioCryst, CSL Behring, Ionis, Pharvaris, Takeda, Intellia, KalVista, Pharming
Consultant: Astria,  BioCryst, CSL Behring, Ionis, Pharvaris, Takeda, Intellia, KalVista, Pharming, Novartis, Amgen, AstraZeneca, GSK, Blueprint, Sanofi, Genentech, Regeneron 
Independent Contractor: Astria, BioCryst, CSL Behring, Ionis, Pharvaris, Takeda, Intellia, KalVista,  Pharming, Cogent, Teva, Octapharma, Merck, Allakos, Celldex, Nocion, GSK
Speaker: Astria,  BioCryst, CSL Behring, Ionis, Pharvaris, Takeda, Intellia, KalVista, Pharming, Novartis, Amgen, AstraZeneca, GSK, Blueprint, Sanofi, Genentech, Regeneron

Maeve O'Connor, MD – Speaker
Advisor: AstraZeneca, Blueprint Medicine, CSL Behring, GSK, Novartis, Regeneron, Sanofi
Consultant: ADMA
Independent Contractor: AstraZeneca, Blueprint Medicine
Speaker: ADMA, Amgen, ARS Pharmaceuticals, AstraZeneca, BioCryst, GSK, Regeneron, Sanofi

Jordan S. Orange, MD, PhD – Speaker
Consultant: CSL Behring, Teva
Researcher: ADMA Biologics
Royalties or Patent Beneficiary: Up To Date

Barbara Ariue, MD – Planner
Speaker: Pharming

Sonal R. Patel, MD – Planner, Moderator
Speaker: Regeneron, Sanofi

Raffi Tachdjian, MD, MPH – Planner, Moderator
Advisor: Astria, Biocryst, CSL Behring, Ionis, Kalvista, Pharming, Pharvaris, Takeda
Independent Contractor: Astria, Biocryst, CSL Behring, Ionis, Kalvista, Pharming, Pharvaris, Takeda
Speaker: ARS, AstraZeneca, Biocryst, CSL Behring, Grifols, GSK, Pharming, Regeneron/Sanofi, Takeda

Matthew Bowdish, MD – Planner
Consultant: GSK
Researcher: GSK
Speaker: AstraZeneca, GSK 

The following have no relevant financial relationships with ineligible companies to disclose:

Javed Sheikh, MD – Planner, Reviewer
Myngoc Nguyen, MD – Planner, Reviewer
Sheila M. Bonilla, MD – Planner
Suzanne Teuber, MD – Planner
Karol Anderson – Planner

Available Credit

  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Attendance
  • 6.50 CBRN
Please login or create an account to take this course.